歡迎您，來到青旗（上海）生物技術(shù)發(fā)展有限公司！
歡迎您，來到青旗（上海）生物技術(shù)發(fā)展有限公司！
您的位置：網(wǎng)站首頁 > 產(chǎn)品展示 > 細胞庫 > 細胞系 > 人非小細胞肺癌細胞NCI-H358
Related articles
簡要描述：青旗（上海）生物技術(shù)發(fā)展有限公司，總部位于上海浦東新區(qū)，依托本地高校資源，逐步發(fā)展成為以生物技術(shù)為主的研發(fā)、生產(chǎn)、培訓(xùn)為一體的綜合化產(chǎn)業(yè)平臺，在標(biāo)準(zhǔn)化細胞庫建立及細胞藥物前端模型方面成果顯著。公司生產(chǎn)經(jīng)營原代細胞、細胞系、ELISA試劑盒、感受態(tài)細胞和HPLC檢測等科研產(chǎn)品與服務(wù)。我們秉承對用戶負(fù)責(zé)的態(tài)度，以對科研的高度嚴(yán)謹(jǐn)，以嚴(yán)格的質(zhì)量控制，為廣大生物醫(yī)學(xué)科研用戶提供更優(yōu)質(zhì)的服務(wù)！
更新時間：2023-06-29
廠商性質(zhì)：生產(chǎn)廠家
瀏覽次數(shù)：616
| 品牌 | 其他品牌 | 貨號 | BFN60800666 |
|---|---|---|---|
| 規(guī)格 | T25培養(yǎng)瓶x1 1.5ml凍存管x2 | 供貨周期 | 現(xiàn)貨 |
| 主要用途 | 僅供科研 | 應(yīng)用領(lǐng)域 | 醫(yī)療衛(wèi)生,生物產(chǎn)業(yè) |
細胞名稱 | 人非小細胞肺癌細胞NCI-H358 |
| |
貨物編碼 | BFN60800666 | ||
產(chǎn)品規(guī)格 | T25培養(yǎng)瓶x1 | 1.5ml凍存管x2 | |
細胞數(shù)量 | 1x10^6 | 1x10^6 | |
保存溫度 | 37℃ | -198℃ | |
運輸方式 | 常溫保溫運輸 | 干冰運輸 | |
安全等級 | 1 | ||
用途限制 | 僅供科研用途 1類 | ||
培養(yǎng)體系 | DMEM高糖培養(yǎng)基（Hyclone）+10%胎牛血清（Gibco）+1%雙抗（Hyclone） | ||
培養(yǎng)溫度 | 37℃ | 二氧化碳濃度 | 5% |
簡介 | 人非小細胞肺癌細胞NCI-H358細胞于1981年從一位開始化療之前的患者的腫瘤組織中分離建株。超微結(jié)構(gòu)研究表明細胞質(zhì)中有Clara細胞的特征結(jié)構(gòu)細胞表達主要的肺表面結(jié)合蛋白SP-A的蛋白和RNA。不表達SP-B和SP-C。他們在軟瓊脂中的克隆形成效率為0.83%。 | ||
注釋 | Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: COSMIC cell lines project. Part of: MD Anderson Cell Lines Project. Part of: NCI RAS program mutant KRAS cell line panel. Doubling time: 38 hours (in RPMI 1640 + 10% FBS), 76 hours (in ACL-3), 60 hours (in ACL-3 + BSA) (PubMed=3940644); 38 hours (ECACC). Microsatellite instability: Stable (MSS) (Sanger). Omics: Deep exome analysis. Omics: Deep phosphoproteome analysis. Omics: Deep proteome analysis. Omics: Deep RNAseq analysis. Omics: DNA methylation analysis. Omics: Protein expression by reverse-phase protein arrays. Omics: SNP array analysis. Omics: Transcriptome analysis. Caution: We are not certain that NCI-H358 and NCI-H358M are identical. Misspelling: H1358; In PubMed=1311061 table 1. | ||
STR信息 | Amelogenin:X,Y；CSF1PO:11，12；D13S317:8，12；D16S539:12，13；D18S51:14；D19S433:13，14；D21S11:28，30；D2S1338:17，23；D3S1358:14，18；D5S818:10,12；D7S820:10，11；D8S1179:13，14；FGA:20,21；TH01:6；TPOX:8，9；vWA:17 | ||
參考文獻 | PubMed=3940644 Brower M., Carney D.N., Oie H.K., Gazdar A.F., Minna J.D. Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. Cancer Res. 46:798-806(1986)
PubMed=3335022 Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48:589-601(1988)
PubMed=2388294; DOI=10.1093/jnci/82.17.1420 McLemore T.L., Litterst C.L., Coudert B.P., Liu M.C., Hubbard W.C., Adelberg S., Czerwinski M., McMahon N.A., Eggleston J.C., Boyd M.R. Metabolic activation of 4-ipomeanol in human lung, primary pulmonary carcinomas, and established human pulmonary carcinoma cell lines. J. Natl. Cancer Inst. 82:1420-1426(1990)
PubMed=2386953 Gazdar A.F., Linnoila R.I., Kurita Y., Oie H.K., Mulshine J.L., Clark J.C., Whitsett J.A. Peripheral airway cell differentiation in human lung cancer cell lines. Cancer Res. 50:5481-5487(1990)
PubMed=1311061 Mitsudomi T., Steinberg S.M., Nau M.M., Carbone D., D'Amico D., Bodner S., Oie H.K., Linnoila R.I., Mulshine J.L., Minna J.D., Gazdar A.F. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 7:171-180(1992)
PubMed=1565469 Bodner S.M., Minna J.D., Jensen S.M., D'Amico D., Carbone D.P., Mitsudomi T., Fedorko J., Buchhagen D.L., Nau M.M., Gazdar A.F., Linnoila R.I. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 7:743-749(1992)
PubMed=8806092; DOI=10.1002/jcb.240630505 Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P., McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr., Carney D.N., Minna J.D., Mulshine J.L. NCI-Navy Medical Oncology Branch cell line data base. J. Cell. Biochem. 63 Suppl. 24:32-91(1996)
PubMed=8806101; DOI=10.1002/jcb.240630514 Lokshin A., Levitt M.L. Effect of suramin on squamous differentiation and apoptosis in three human non-small-cell lung cancer cell lines. J. Cell. Biochem. 63 Suppl. 24:186-197(1996)
PubMed=9649128; DOI=10.1038/bjc.1998.361 Yi S., Chen J.-R., Viallet J., Schwall R.H., Nakamura T., Tsao M.-S. Paracrine effects of hepatocyte growth factor/scatter factor on non-small-cell lung carcinoma cell lines. Br. J. Cancer 77:2162-2170(1998)
PubMed=11030152; DOI=10.1038/sj.onc.1203815 Modi S., Kubo A., Oie H., Coxon A.B., Rehmatulla A., Kaye F.J. Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer. Oncogene 19:4632-4639(2000)
PubMed=11369051; DOI=10.1016/S0165-4608(00)00363-0 Luk C., Tsao M.-S., Bayani J., Shepherd F., Squire J.A. Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization. Cancer Genet. Cytogenet. 125:87-99(2001)
PubMed=12068308; DOI=10.1038/nature00766 Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A. Mutations of the BRAF gene in human cancer. Nature 417:949-954(2002)
PubMed=18083107; DOI=10.1016/j.cell.2007.11.025 Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J., Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L., Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J., Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131:1190-1203(2007)
PubMed=19472407; DOI=10.1002/humu.21028 Blanco R., Iwakawa R., Tang M., Kohno T., Angulo B., Pio R., Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M. A gene-alteration profile of human lung cancer cell lines. Hum. Mutat. 30:1199-1206(2009)
PubMed=20164919; DOI=10.1038/nature08768 Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R. Signatures of mutation and selection in the cancer genome. Nature 463:893-898(2010)
PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458 Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A. A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Res. 70:2158-2164(2010)
PubMed=22460905; DOI=10.1038/nature11003 Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603-607(2012)
PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112 Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P., Yordy J., Giri U., Peyton M., Fan Y.H., Diao L., Masrorpour F., Shen L., Liu W., Duchemann B., Tumula P., Bhardwaj V., Welsh J., Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L., Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D., Heymach J.V. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2:798-811(2012)
PubMed=24135919; DOI=10.1038/ncomms3617 Balbin O.A., Prensner J.R., Sahu A., Yocum A., Shankar S., Malik R., Fermin D., Dhanasekaran S.M., Chandler B., Thomas D., Beer D.G., Cao X., Nesvizhskii A.I., Chinnaiyan A.M. Reconstructing targetable pathways in lung cancer by integrating diverse omics data. Nat. Commun. 4:2617-2617(2013)
PubMed=25485619; DOI=10.1038/nbt.3080 Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z. A comprehensive transcriptional portrait of human cancer cell lines. Nat. Biotechnol. 33:306-312(2015)
PubMed=27397505; DOI=10.1016/j.cell.2016.06.017 Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J. A landscape of pharmacogenomic interactions in cancer. Cell 166:740-754(2016)
PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005 Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H. Characterization of human cancer cell lines by reverse-phase protein arrays. Cancer Cell 31:225-239(2017)
PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051 Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W., Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D., Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E., Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C., Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H., McCormick F. Differential effector engagement by oncogenic KRAS. Cell Rep. 22:1889-1902(2018)
PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747 Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A. An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines. Cancer Res. 79:1263-1273(2019)
PubMed=31068700; DOI=10.1038/s41586-019-1186-3 Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569:503-508(2019) | ||
驗收細胞注意事項
1、收到人非小細胞肺癌細胞NCI-H358細胞，請查看瓶子是否有破裂，培養(yǎng)基是否漏出，是否渾濁，如有請盡快聯(lián)系。
2、收到人非小細胞肺癌細胞NCI-H358細胞，如包裝完好，請在顯微鏡下觀察細胞。,由于運輸過程中的問題，細胞培養(yǎng)瓶中的貼壁細胞有可能從瓶壁中脫落下來，顯微鏡下觀察會出現(xiàn)細胞懸浮的情況，出現(xiàn)此狀態(tài)時，請不要打開細胞培養(yǎng)瓶，應(yīng)立即將培養(yǎng)瓶置于細胞培養(yǎng)箱里靜止 3-5 小時左右，讓細胞先穩(wěn)定下，再于顯微鏡下觀察，此時多數(shù)細胞會重新貼附于瓶壁。如細胞仍不能貼壁，請用臺盼藍染色法鑒定細胞活力，如臺盼藍染色證實細胞活力正常請按懸浮細胞的方法處理。
3、收到人非小細胞肺癌細胞NCI-H358細胞后，請鏡下觀察細胞，用恰當(dāng)方式處理細胞。若懸浮的細胞較多，請離心收集細胞，接種到一個新的培養(yǎng)瓶中。棄掉原液，使用新鮮配制的培養(yǎng)基，使用進口胎牛血清。剛接到細胞，若細胞不多時 血清濃度可以加到 15％去培養(yǎng)。若細胞迏到 80%左右 ，血清濃度還是在 10％。
4、收到人非小細胞肺癌細胞NCI-H358細胞時如無異常情況 ，請在顯微鏡下觀察細胞密度，如為貼壁細胞，未超過80%匯合度時，將培養(yǎng)瓶中培養(yǎng)基吸出，留下 5-10ML 培養(yǎng)基繼續(xù)培養(yǎng)：超過 80%匯合度時，請按細胞培養(yǎng)條件傳代培養(yǎng)。如為懸浮細胞，吸出培養(yǎng)液，1000 轉(zhuǎn)/分鐘離心 3 分鐘，吸出上清，管底細胞用新鮮培養(yǎng)基懸浮細胞后移回培養(yǎng)瓶。
5、將培養(yǎng)瓶置于 37℃培養(yǎng)箱中培養(yǎng)，蓋子微微擰松。吸出的培養(yǎng)基可以保存在滅菌過的瓶子里，存放于 4℃冰箱，以備不時之需。
6、24 小時后，人非小細胞肺癌細胞NCI-H358細胞形態(tài)已恢復(fù)并貼滿瓶壁，即可傳代。（貼壁細胞）將培養(yǎng)瓶里的培養(yǎng)基倒去，加 3-5ml（以能覆蓋細胞生長面為準(zhǔn)）PBS 或 Hanks’液洗滌后棄去。加 0.5-1ml 0.25%含 EDTA 的胰酶消化，消化時間以具體細胞為準(zhǔn)，一般 1-3 分鐘，不超過 5 分鐘?？梢苑?/span>入37℃培養(yǎng)箱消化。輕輕晃動瓶壁，見細胞脫落下來，加入 3-5ml 培養(yǎng)基終止消化。用移液管輕輕吹打瓶壁上的細胞，使之*脫落，然后將溶液吸入離心管內(nèi)離心，1000rpm/5min。棄上清，視細胞數(shù)量決定分瓶數(shù)，一般一傳二，如細胞量多可一傳三，有些細胞不易傳得過稀，有些生長較快的細胞則可以多傳幾瓶，以具體細胞和經(jīng)驗為準(zhǔn)。（懸浮細胞）用移液管輕輕吹打瓶壁，直接將溶液吸入離心管離心即可。
7、貼壁細胞 ，懸浮細胞。嚴(yán)格無菌操作。換液時，換新的細胞培養(yǎng)瓶和換新鮮的培養(yǎng)液，37℃，5%CO2 培養(yǎng)。
特別提醒： 原瓶中培養(yǎng)基不宜繼續(xù)使用，請更換新鮮培養(yǎng)基培養(yǎng)。
地址：上海市浦東新區(qū)宏祥北路83號
郵箱：cellsupport@bluefcell.com
傳真：
咨詢電話